Dr. August Wolff Arzneimittel GmbH & Co. KG and Mercachem B.V. start two drug development collaborations
Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem have started two multi-year drug development collaborations. Dr. August Wolff GmbH & Co. KG Arzneimittel have licensed a number of patents from universities that cover novel classes of molecules with potential use in dermatology. Mercachem is responsible for medicinal chemistry and project management with the goal to further improve the properties of these molecules and to develop them into clinical candidates.
‘We are of course very pleased that Dr. August Wolff GmbH & Co. KG Arzneimittel has selected Mercachem as its partner to help the company with the new strategy to focus more on the development of novel innovative products’ says Frank Leemhuis, Managing Director of Mercachem, ‘We believe that our reputation for delivering high quality work and creating novel molecules besides our excellent synthetic skills have contributed to the positive decision of Dr. August Wolff GmbH & Co. KG Arzneimittel to work with us.’
Professor Christoph Abels, Medical Director, comments: ‘Dr. August Wolff GmbH & Co. KG Arzneimittel wants to introduce novel and safe products in the areas of dermatology and gynecology as fast as possible into the market. Working in the field of drug development without a large in-house research team geared for this purpose, our strategy is to rely on high-quality service providers that offer ‘fit-for-purpose’ solutions and complement our knowledge. Since Dr. August Wolff GmbH & Co. KG Arzneimittel is looking for alternative approaches to solve unmet medical needs, we believe that the people at Mercachem meet our needs as an innovative family business most adequately.’
Other news from the department business & finance
